Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER's Drug-Drug Interaction Database Will Be Functional By 2000

Executive Summary

CDER's drug-drug interaction scientific database will be functional two years ahead of schedule, FDA's fiscal 1999 revision to the Prescription Drug User Fee Act Information Management Plan indicates.

You may also be interested in...



User Fee Revision Reduces Expected CDER Staffing Increases By 139 FTEs

A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.

User Fee Revision Reduces Expected CDER Staffing Increases By 139 FTEs

A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.

Electronic Full NDA Filings Projected By Mid-1999; 14% User Fees Go To IT

FDA's electronic submissions program will be equipped to accept full NDA submissions by September 1999, FDA reported in its Prescription Drug User Fee Act Information Management Five-Year Plan, released with the PDUFA II Five-Year Plan on July 10.

Related Content

UsernamePublicRestriction

Register

PS034742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel